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Summary
We aim to identify current in vitro research explor-
ing platelet-rich plasma (PRP) effects in human
Mesenchymal Stem Cells (MSCs) that may encour-
age or limit the clinical application of MSCs along
with PRP. After a systematic search, we identified
57 in vitro studies, focused on optimization of
MSC manufacturing, and expanding knowledge
about how PRP modifies MSCs behavior for trans-
lational purposes. Influences of PRP on prolifera-
tion, migration, stemness, preservation of MSC
immune-modulatory properties and appearance of
senescence phenotype have been explored. Over-
all PRP stimulates MSC proliferation, preserves
MSCs multipotency and does not interfere with
any lineage differentiation. PRP (as platelet lysate
or releasate) preserves the immune-privileged po-
tential of MSCs and may delay the appearance of
the senescent phenotype. Currently there are few
data linking precise molecules and biological
mechanisms. Various gaps of knowledge need to
be addressed in order to obtain enough useful in-
formation for translational purposes.
KEY WORDS: cell culture, in vitro, mesenchymal stem cells
(MSC), platelet-rich plasma (PRP), regenerative medicine,
tissue engineering.
Introduction
The use of mesenchymal stem cells (MSCs) for tissue
healing and Regenerative Medicine research has
been extended in the last decade. Three accepted
MSCs capabilities are centrally involved in their regen-
erative properties. First, their potential to differentiate
into tissue specific cells, second their ability to influ-
ence the fate of other cell types through paracrine sig-
naling and third their immune-modulatory potential
through secretion of prostaglandins such as PGE21. It
was Caplan2 in 1991 who proposed the MSC defini-
tion, currently adopted by the International Society for
Cellular Therapy (ISCT), based on three main criteria:
first, MSC adhesion to plastic; second, their expres-
sion of a set of membrane molecules (CD73, CD90,
CD105), together with a lack of expression of HLA-DR
and absence of hematopoietic and endothelial mark-
ers CD11b, CD14, CD34, CD31, and CD45; and, third
their ability to differentiate along adipogenic, os-
teogenic, and chondrogenic pathways3, 4.
Current research in MSCs aims not only to the devel-
opment of cell therapies in regenerative medicine, but
to provide experimental models that can inform about
molecular mechanisms such as inflammation, angio-
genesis and apoptosis among others. For these pur-
poses and because of their accessibility, MSCs are
most commonly isolated from the bone marrow (BM-
SC), or the adipose tissue (ADSC), and then grown in
2D or 3D conditions. 
In vivo MSCs activities are regulated by the molecular
microenvironments that modulate their anabolic status.
Thus, signaling factors in the microenvironment instruct
MSCs to remain quiescent, proliferate, migrate, and/or
differentiate. In this context, autologous formulations
derived from own patient’s blood, named platelet rich
plasma technologies are being developed to be used
alone or in association with cells for regenerative medi-
cine purposes. The foundation of PRP use is the re-
lease of a pool of signaling factors that will create a
pro-healing environment in the injured site. 
The first description of Platelet Rich Plasma when it
was introduced as a MeSH (Medical Subject Head-
ings) term in 2007 is: “a preparation consisting of
PLATELETS concentrated in a limited volume of
PLASMA. This is used in various surgical tissue re-
generation procedures where the GROWTH FAC-
TORS in the platelets enhance wound healing and re-
generation”. Growth factors (GFs) from PRP have
their source in alpha granules from platelets (50-80
per platelet). However, recent proteomic studies have
revealed the complexity of platelet secretome, and in-
dexed not only GFs but a vast array of molecules in-
cluding cytokines and chemokines, adhesive pro-
teins, enzymes, fibrinolytic and antifibrinolytic pro-
teins. This molecular pool is released upon platelet
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activation that is the interaction of molecules such as
collagen, thrombin, platelet-activating factor, sero-
tonin, calcium, magnesium, thromboxane A2, and
adenosine di-phosphate with platelet receptors. Also,
mechanical disruption of platelets causes their activa-
tion and the subsequent release of their content.
When platelets are activated, there is an initial burst
of GFs that is lately stabilized and maintained in a
sustained release.
The aim of the present systematic review is to evalu-
ate the relevance of current preclinical research to-
wards the development of combination products (bio-
logical therapies) that may encourage or limit the
clinical application of MSCs along with PRP. There-
fore, we will discuss MSCs effects in proliferation,
differentiation, migration and immune modulation
and report on the controversial results obtained by
different authors due to the heterogeneity of PRP
formulations, and the different conditions used in
MSCs cultures.
Methods 
A systematic literature search5 was performed from
January 2007 to October 2013 in Pubmed, Web of
Knowledge and Google Scholar. As keywords, we
have used Platelet Rich Plasma AND/OR Platelet
Lysate AND/OR Platelet Releasate AND Mesenchy-
mal Stem Cells.
Inclusion criteria
The search was limited to “humans” and English lan-
guage. Articles presenting bone as a MeSH major top-
ic were excluded. Only original journal and classical
articles (not reviews or clinical trials) were included.
Extraction of data
Title and abstracts were screened by two researchers
independently, and the full text of the selected arti-
cles was read by both reviewers. The following data
were extracted: cell source, platelet count, leukocyte
content, whether the study was performed with the
PRP from single or pooled donors, the biological
mechanism that was evaluated, i.e. proliferation, dif-
ferentiation, cell morphology or immunomodulation. 
We classified PRPs according to the categorization
system made by Delong JM et al6. Briefly, 1x platelet
count above baseline or less is considered low
platelet content, 1x-4x is a moderate platelet concen-
tration, 4x-6x is a high content and 6x or more is su-
per high content. Finally studies were sorted in two
groups based on their main intended goal: 1) re-
search studies (2D or 3D studies) and 2) cell produc-
tion studies. To accomplish this goal, these authors
perform long term proliferation studies and calculate
cell population doublings through cell passages. They
also check MSCs viability at high passages by testing
Muscles, Ligaments and Tendons Journal 2014; 4 (1): 52-62 53
Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience
phenotype, differentiation capacity and even chromo-
somal stability and senescence markers.
Results
Study selection
Using the above described search algorithm, we
found 277 articles of which 143 articles had been per-
formed with human cells, and were written in English.
After excluding reviews and articles pertaining to den-
tal and bone biology, and adding hand search rele-
vant articles, we included 57 articles as relevant to
research in biological mechanisms, of which 22 arti-
cles perform large scale MSC production. Twelve arti-
cles perform studies on Adipose Stem Cells (AD-
SCs)7-18 (Tab. 1). 36 articles study PRP biological ef-
fect in BMSCs19-55 (Tab. 2), and 8 others on several
stem cell types including ADSCs, BMSCs and Umbili-
cal Cord MSCs (UCMSCs)56-63 (Tab. 3).
PRP formulations
The different procedures for PRP preparation pro-
duce different compositions that may account for re-
sult variability. Most often the two step centrifugation
is used to separate blood components, and to con-
centrate platelets (and optionally leukocytes) in the fi-
nal PRP product. Alternatively, one centrifugation
step generates a PRP product with a moderate/low
concentration of platelets depending on centrifugal
force and time. Overall, we found that in “PRP+MSC”
research there is a slightly higher use of PRPs with
high or super high concentrations of platelets (Fig. 1).
Leukocyte content in PRP
Leukocyte content influences the molecular composi-
tion in PRP. However, most of the in vitro studies
don’t even mention leukocyte content in their final
product. Leukocyte content in PRP samples is merely
described by two authors21,62.
PRP activation methods
About 85% of the studies perform freeze/thaw cycles
to cause mechanical disruption of platelet mem-
branes and release alpha granule content. When
those steps are performed, they proceed to filtration
through 0.22 um filters and addition of heparin
(2U/ml) to the lysates35,40,57. This procedure is the
most commonly found in the papers studied, but
there are some authors which prefer performing
chemical activation instead of thermic/mechanical ac-
tivation and use of thrombin and/or calcium chlo-
ride7,17,34,41,45,49. In general, bovine thrombin is used
except for Vogl24 who obtains human thrombin from
blood donations. Thrombin and/or CaCl2 trigger clot
formation, and after incubation the liquid extruded
from the clot is collected. This PRP fraction is called
PRP releasate or supernatant.
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MSC+PRP: assessment of biological effects
(Tabs. 1-3)
Proliferation: PRP and MSCs large expansion in
CMOs
The goal of these studies was to establish the best
conditions for large-scale expansion of MSCs in cell
manufacturing facilities in terms of safety, cost and
time. The main goal was to substitute with PRP the
xenogenic component of cell expansion, i.e. FBS (fe-
tal bovine serum). 23 articles out of the 57 selected
for this review perform long term expansion studies,
and are indicated with * in Table 1, 2 and 3. These
studies primarily calculate cell population doublings
through cell passages and population doubling times.
They also check MSCs viability at high passages by
testing CFU-f (colony-forming unit-fibroblast), pheno-
type, differentiation capacity and even chromosomal
stability and senescence markers. In all the articles,
PRP increases the number of cell population dou-
blings, and decreases the time necessary for the pop-
ulation to duplicate. Of note, methodological differ-
ences inter studies, including initial cell seeding con-
centration, MSC passage number conditions, renewal
of the medium, and time of the experiment difficult
comparisons.
Importantly, PRP delays the appearance of the
senescence phenotype12,26,42,60, and protects from
chromosomal instability longer than FBS, which has
traditionally been used in MSC laboratory cultures. 
Tissue engineering 
In order to assess MSCs+PRP application in tissue
engineering, 3D proliferation studies in different bio-
materials used for the development of tissue grafts
have been performed.
These studies are displayed with “#” in Table 1 and 2.
PRP can be incorporated in a gel or powdered form
to the 3D scaffold, generally used for bone or carti-
lage tissue engineering. Other studies examine
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Table 1. Cell culture studies performed with Adipose Derived Stem Cells and Platelet Rich Plasma.
ADIPOSE DERIVED STEM CELLS (ADSCs)
BIOLOGICAL EFFECTS (PRP vs FBS)
Stemness
Author, year, Platelet count Proliferation Migration Immune
[reference] Pool or single modulation Chondr. Adipo. Osteo.
donor
Van Pham Super high (6x) Enhanced - - Enhanced Similar Similar
2013 [7] Single donor
Hildner - Enhanced - - Enhanced - -
2013 [8]* -
Chen L. Super high (6x) Enhanced - - - - Enhanced
2012 [9]# Single donor
Cervelli - Enhanced - - - Enhanced -
2012 [10] Pool with insulin
Sell High (3.82x) Enhanced Enhanced - - -
2011 [11]# Pool
Shih - Enhanced - - Enhanced Similar Similar
2011 [12]* Single donor
Cholewa Super high (6.2x) Enhanced - - - Similar Similar
2011 [13]* Pool
Chieregato Moderate (2x) Enhanced - - Similar Enhanced Enhanced
2011 [14]* -
Castegnaro Moderate (2.74x) Enhanced - Enhanced - Similar Similar
2011 [15]* Pool
Souza Blande Moderate (3.64x) Enhanced - - - Similar Similar
2009 [16]* Single donor
Kakudo Super High (7.9x) Enhanced - - - - -
2008 [17] Single donor
Kocaoember Super high (10x) Enhanced - - - Similar Similar
2007 [18]* Pool
* Articles performing long term expansion studies; # Articles performing 3D studies. 
Abbreviations: ADSCs, Adipose Derived Stem Cells; PRP, Platelet Rich plasma; FBS, Fetal bovine serum; Chondr, Chon-
drogenic; Adipo., Adipogenic; Osteo., Osteogenic. 
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Table 2. Cell culture studies performed with Bone Marrow derived Stem Cells and Platelet Rich Plasma.
BONE MARROW STEM CELLS
BIOLOGICAL EFFECTS (PRP vs FBS)
Stemness
Author, year, Platelet count Proliferation Migration Immune Chondr. Adipo. Osteo.
[reference] Pool or single modulation
donor
P.H. Warnke - Enhanced - - - Similar Similar
2013 [19]# Pool
Jonsdottir- - Enhanced - Similar Similar Similar Similar
Buch 2013[20]* Pool
Schallmoser Moderate (3.8x) Enhanced - - - - -
2013 [21] Pool
Leotot High (4x) Enhanced - - - - Enhanced
2013 [22]# Pool
Copland High (4x) Enhanced - Enhanced - - -
2013 [23] Pool when 
fibrinogen 
depletion
Vogl 2013 [24] Moderate (3.9x) Enhanced - - - - similar
Pool
Mojica-Henshaw High (4.3x) Enhanced - - Similar Similar Similar
2013 [25] Pool
Griffiths - Enhanced - - - -
2013 [26]* Pool
Gottipamula - Enhanced - Decreased Enhanced Similar Enhanced
2012 [27]* Pool
Fekete - Enhanced - - Similar Similar Similar
2012 [28]* Pool
Teixeira - Enhanced Enhanced - Enhanced Similar Similar
2012 [29]# Single donor
Walenda Super high (8.4x) Enhanced - Similar Similar Similar
2012 [30]*# Pool
Ben Azouna Moderate (3.8x) - - - Similar Similar Similar
2012 [31] Pool
Murphy MB High (4x) Enhanced Enhanced - - - -
et al 2012 [32] Single donor
Fekete High (≥4x) - - - Similar Similar Similar
2012 [33] Pool
Cho 2011 [34] High (4.65x) Enhanced - - - - -
Single donor
Xia 2011 [35] High (5x) Enhanced - - - Decreased Enhanced
Single donor
Flemming - Enhanced - Similar - - -
2011 [36] Pool
Abdelrazik Super high (10x) Enhanced - Decreased - - -
2011 [37]* Pool
Goedecke Low (≤1x) Enhanced Decreased - - Similar Similar
2011 [38] Single donor
Lange - - - - - Decreased -
2011 [39] Pool
Horn Super high (6.2x) Enhanced - - - Similar Enhanced
2010 [40]* Pool
to be continued
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MSCs-scaffold constructs with culture medium sup-
plemented with PRP, and observed not only en-
hanced cell proliferation but improved cell loading in-
to the scaffolds49. PRP benefits have also been re-
ported in terms of cell adhesion and colonization of
the biomaterial scaffold29. 
MSC migration
MSC migration is investigated in few stud-
ies11,29,32,38all but one showed enhanced MSC migra-
tion in PRP comparing to FBS29,32. Moreover, Mur-
phy32 et al. have compared ucPRP (umbilical cord
PRP), aPRP (adult PRP), aPPP and FBS effect in
MSC migration and found that all forms of human
plasma were much more effective in promoting cell
migration than FBS. 
Cell differentiation
MSCs characteristically differentiate into multiple
mesoderm-derived cell types including adipocytes,
chondrocytes and osteoblasts. Aiming to develop ar-
ticular therapies by combining PRP and MSCs, Mishra
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Table 2. (cont.) Cell culture studies performed with Bone Marrow derived Stem Cells and Platelet Rich Plasma.
BONE MARROW STEM CELLS
BIOLOGICAL EFFECTS (PRP vs FBS)
Stemness
Author, year, Platelet count Proliferation Migration Immune Chondr. Adipo. Osteo.
[reference] Pool or single modulation
donor
Lucarelli Moderate (2.1x) Enhanced - - - - -
2010 [41]# Single donor
Schallmoser Moderate (3.8x) - - - - Similar Similar
2010 [42] Pool
Chevallier High (≥4x) Enhanced - - Similar - Enhanced
2010 [43]# -
Mishra Super High (7x) Enhanced - - Enhanced - -
2009 [44] Single donor
Huang Super high (6.6x) Enhanced - - - - -
2009 [45] Single donor
Pérez-Ilzarbe Super high (6x) Enhanced - Enhanced Similar Similar Similar
2009 [46] Pool
Prins High (4x) Enhanced - - Similar Similar Similar
2009 [47]# Pool
Zaky High (5.6x) Enhanced - - Enhanced - Similar
2008 [48]* Single donor
Kasten High (4.2x) Enhanced - - - Similar
2008 [49]# Pool
Carrancio - Enhanced - - Similar Similar Similar
2008 [50] Pool
Schallmoser Moderate (3.8x) Enhanced - - Similar Similar Similar
2008 [51]* Pool
Schalmosser Moderate (3.8x) Enhanced - - - Similar Similar
2007 [52] Pool
Capelli High (4.8x) Enhanced - Similar - Similar Similar
2007 [53]* Single donor
Bernardo Super high (10x) Enhanced - Decreased - Similar Similar
2007 [54]* Pool
Lange Moderate (4x) Enhanced - Enhanced Similar Similar Similar
2007 [55]* Pool
* Articles performing long term expansion studies; #Articles performing 3D studies 
Abbreviations: BMSCs, Bone Marrow derived Stem Cells; PRP, Platelet Rich plasma; FBS, Fetal bovine serum; Chondr.,
Chondrogenic; Adipo., Adipogenic; Osteo., Osteogenic.
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et al.44 showed that buffered PRP enhanced the ex-
pression of chondrogenic markers, such as Sox9 and
Aggrecan. These findings were corroborated in further
studies7,8,12,27,29,47 that showed enhanced chondro-
genic differentiation, and extracellular cartilage matrix
synthesis in the presence of PRP. Likewise, Shih et
al.12 also proved that chondrogenic differentiation was
enhanced and maintained through cell passages in
PRP cultures comparing to FCS cultures. Moreira
Teixeira29 proved that chondrogenic differentiation in
dextran based scaffolds was enhanced by the addition
of PRP in the form of platelet lysate (PL). Interestingly
PRP did not hinder chondrogenic differentiation in any
of the studies reviewed here.
Besides, PRP did not interfere with osteogenic differ-
entiation and most authors found similar osteogenic
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Table 3. Cell culture studies performed with Bone Marrow derived Stem Cells and Adipose Derived Stem Cells or
Umbilical Cord Derived Mesenchymal Stem Cells (UCMSCs) and Platelet Rich Plasma.
SEVERAL STEM CELL SOURCES
BIOLOGICAL EFFECTS (PRP vs FBS)
Stemness
Author, Platelet Cell Proliferation Migration Immune Chondr. Adipo. Osteo.
year, count source modulation
[reference] Pool or 
single 
donors
Hemeda Super BMSCs Decreased at - - - Decreased Decreased
2013 [56] high (6.2x) and high heparin at high at high 
Pool ADSCs concentrations heparin heparin
concentrations concentration
Lohmann Super high BMSCs Enhanced - - - Similar Decreased
2012 [57] (6.2x) and with old d.
Single ADSCs
donors
Menard - BMSCs - - Enhanced - - -
2013 [3] Pool and in ADSCs
ADSCs
Torensma - BMSCs - Decreased - - -
2013 [58]* Pool and
ADSCs
Jenhani - UCMSCs Enhanced - - - - -
2011 [59]* Pool and
BMSCs
Crespo- - BMSCs Enhanced - - Similar Similar Similar
Diaz Pool and 
2011 [60]* ADSCs
Avanzini Super high UCMSCs - - - - - -
2009 [61]* (10x) and 
Pool BMSCs
Reinisch Moderate UCMSCs Decreased in - Similar Similar Decreased Similar
2007 [62] (3.8x) late passages
Pool
* Articles performing long term expansion studies 
Abbreviations: ADSCs, Adipose Derived Stem Cells; BMSCs, Bone Marrow derived Stem Cells; UCMSCs, Umbilical Cord
Derived Mesenchymal Stem Cells; PRP: Platelet Rich plasma; FBS: Fetal bovine serum; Chondr.: Chondrogenic; Adipo.:
Adipogenic; Osteo.: Osteogenic.
Figure 1. Sectors illustrating the use of different PRP for-
mulations (according to De Long Classification [ref. 5]) in
vitro studies of mesenchymal stem cells and PRP.
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differentiation capacity when using one or the other
supplement (PRP versus FBS). Albeit few studies
have shown that PRP enhanced MSCs osteogenic
differentiation in 2D cultures14,27,35,40 and in 3D cul-
tures9,22,43. Interestingly, Hemeda et al.56 found re-
duced osteogenic differentiation when MSCs where
cultured with PRP with high heparine concentrations
which were used to avoid PRP clotting. Also,
Lohmann et al.23 found less osteogenic differentiation
capacity in stem cells cultured with PRP obtained
from old donors.
In the same trend, adipogenic differentiation was simi-
lar with PRP or FBS. Yet, Chieregato14 observed en-
hanced adipogenic differentiation of ADSCs cultured
with PRP, as well as Cervelli10, but in the latter case
only when PRP was combined with insulin. On the
contrary, Reinisch62 and Lange39 observed decreased
adipogenesis when ADSCs and BMSCs where cul-
tured with PRP, respectively. As occurred in chondro-
genesis and osteogenesis assays, high heparin con-
centrations interfered with adipogenic differentiation56.
The fact that PRP supplementation preserves multi-
potency of MSCs, and does not interfere with any lin-
eage differentiation, establishes it as a suitable sub-
stitute for FBS.
Modulation of the immune response 
MSCs can modulate the immune response by sup-
pressing the proliferation of T lymphocytes, as shown
in coculture models15. Furthermore, MSCs can inhibit
proliferation and function of other adaptive immune
cells including B cells, NK cells and dendritic cells55.
Additionally MSCs alter the cytokine secretion profile
of immune cells generating an anti-inflammatory phe-
notype. MSCs cultured with PRP (in the form of
platelet lysate or releasate) preserve their immune-
privileged potential as shown by suppression of T-cell
proliferation20,36,53,55,62 and activation46. Interestingly,
the immune potential of MSCs was enhanced when
cultured with fibrinogen-depleted PRP23. In fact, fib-
rinogen compromised the ability of MSCs to up-regu-
late indoleamine dioxygenase that negatively corre-
lates with T-cell proliferation23. 
Remarkably, super-high concentration of platelets
(10x) impaired MSC inhibitory effect on T-cells37,54
and NK-cells, and stimulate secretion of IL-6, IL-8
and RANTES while decreasing PGE237. 
Discussion
As shown in this review, in vitro research in the field
“PRP+MSC” is focused on two main areas, first opti-
mization of the manufacturing process for mesenchy-
mal stem cell therapy purposes, and second expand-
ing the knowledge about how PRP modifies MSCs
behavior for translational purposes, that is to say en-
hancement of PRP therapies, or design of the new
combination products primarily based on “PRP+
MSCs”. 
Three central mechanisms are investigated in the in
vitro models including: proliferation, migration, and
the maintenance of the differentiation potential. In ad-
dition, the influence of PRP in the immune-modulato-
ry properties of MSCs as well as the appearance of
the senescence phenotypehas been explored.
There is no doubt that any PRP formulation (L-PRP,
pure PRP, lysate, releasate) activates MSC prolifera-
tion in a controlled non-tumorigenic manner, a prop-
erty that is of great value not only for cell manufactur-
ing, but also for the clinical applications. Also, PRP is
a useful tool to be incorporated in tissue engineering
as it acts as a stimulator for cells to proliferate and
colonize the scaffold.
Merely three studies11,29,32 have explored the poten-
tial of PRP to induce MSC migration. The chemotac-
tic properties of PRP on MSCs can be partially attrib-
uted to the chemokine SDF-1a (stromal derived factor
1, CXCL12) stored in the alpha granules63,64. This cy-
tokine acts via CXCR-4 promoting cell migration and
homing. Whether PRP enhances precursor cell mi-
gration is crucial in order to augment the efficiency of
bone marrow stimulating techniques, i.e. drilling to
subchondral bone as performed in knee pathology
and rotator cuff65,66. These conditions illustrate the
importance of augmenting cell migration, and the rel-
evance of translational research in PRPs in getting
the essential knowledge to design successful thera-
pies. Thus, the need is clear to augment our knowl-
edge, and introduce procedural modifications that
may help to control the migration, proliferation and
differentiation of these cells for successful healing. 
Regarding differentiation, our Review shows that
PRP maintains stemness and does not hinder differ-
entiation to bone, cartilage or fat, when the appropri-
ate factors are added to the culture media.
Cell cultures are a useful tool to design models that
help to elucidate molecular mechanisms, and identify
specific molecules involved therein. However, linking
specific molecules with biological mechanisms is
challenging, and results are not conclusive yet. For
example, proliferation illustrates how difficult it is to
link detailed molecules with biological mechanisms.
Aiming to identify the main factors involved in prolifer-
ation, Horn et al.40 denoted PDGF-AB and IGF as re-
sponsible for proliferation. Accordingly, Huang et al.45
separated PRP in different fractions according to their
molecular weight, and found that the fractions in
which there was higher PDGF-AB and TGF-β1 con-
tent were the ones that enhanced MSC proliferation
the most. The contribution of TGF-β1 to proliferation
was confirmed by Cho HS et al.34. Notwithstanding,
Lohmann et al.57 reported a lack of correlation be-
tween the concentrations of PDGF-AB, bFGF, TGF-
β1 and IGF-1,and proliferation. Fekete et al.28 found
that proliferation decreased when inhibition of PDGF-
BB and b-FGF was performed. Moreover, the
strongest inhibition was observed when combinations
of anti-bFGF and anti-PDGF-BB or anti-bFGF + anti-
TGFβ + anti-PDG-BB were used. On the contrary,
when different combinations of recombinant PDGF-
BB, bFGF and TGF-β were added to platelet poor
Muscles, Ligaments and Tendons Journal 2014; 4 (1): 52-6258
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plasma, cell proliferation wasn’t promoted14. This is in
accordance with similar experiments performed in
tenocytes67. This paradox can be explained assuming
that the proliferative potential stems from molecular
redundancy, and a delicate balance between multiple
pro- and anti-proliferative molecules68. 
Likewise, increasing PRP percentage in cultures
does not necessarily increase proliferation; 10% PRP
seemed to be the optimal19,21,36,57, and increasing up
to 30% PRP didn’t enhance proliferation but lowered
it compared to FBS. 
These results are relevant for cell manufacturing or-
ganizations where large-scale expansion of MSCs is
performed according to Good Manufacturing Practice
(GMP) procedures. To date, conventional MSC cul-
ture systems involve the use of about 10% of FBS
(fetal bovine serum) in culture medium, but recently
there is an emerging interest to avoid its use, due to
the risk of xenogeneic immune reactions provoked by
FBS antigens18,57. Also, it has been reported that
FBS can be implicated in prion transmission, and its
therapeutic use is not recommended by European
legislation69. Furthermore, it is complicated to use
FBS in a controlled, reproducible manner, because of
its complex composition, with varying efficacy. Hu-
man platelet rich plasma (PRP), in the form of platelet
lysates (HPL) or releasates, have emerged as possi-
ble substitutes for FBS because of their autologous,
non-immunogenic features, and adequate physiologi-
cal composition. Indeed, currently PRPs are commer-
cialized for cell expansion purposes and even lysates
resulting from expired platelet bags obtained from
blood banks seem to be adequate as substitutes of
FBS and provide the same good results as freshly
isolated PRPs20. 
In the present review, we have identified several
sources of variability in PRP technology that may in-
fluence the efficiency of large-scale expansion, and
also the above described biological mechanisms.
First, the formulation i.e. platelet and leukocyte count
in a given volume of plasma, second, the activation
procedure, and lastly the inter-individual variability.
The composition of PRP depends on the preparation
methodology, i.e. single versus double spinning70,71.
Final platelet concentration ranges from 1x above
baseline35 to 12x18. The most commonly used platelet
concentration in vitro ranges between 3x and 6x. It is
known that there is a variation in platelet content pro-
duced not only by preparation methods, but influenced
by inter-and intra-donor variations. The latter include
factors related to patient state, i.e. hydration status,
inflammation, lipemia, diet or circadian rythms72.
To avoid inter-donor variations in PRPs and optimize
reproducibility, several author use pooled PRP from at
least ten donors55. Alternatively, other authors27,36 pool
PRPs from donors of the three blood groups, whereas
others pool blood from the O group in order to avoid
the presence of blood group determinants and isoag-
glutinins21. In this review, 30% of the articles use sin-
gle donor´s PRP whereas 70% use pooled PRPs.
The age of donors is a crucial parameter to be con-
sidered because it significantly affects PRP biology.
For instance, MSCs proliferation is higher with PRP
from young donors while MSCs cultured with PRP
from elder donors can have diminished proliferation,
present a senescence phenotype34,57, and hindered
differentiation capabilities to specific lineages57. 
In clinical applications, L-PRPs often contain concen-
tration of leukocytes above peripheral blood. Al-
though they contribute to increase the pool of GFs,
they also release active cytokines that are primarily
catabolic or inflammatory, e.g. IL1β, TNF-α, IFN-γ73.
Moreover leukocytes release degrading enzymes,
mainly lysozymes and elastases that compromise the
stability of GFs as well as gelatinases and metallo-
proteases, catabolic for collagen proteins. 
Clinicians have to be careful when making sense of
laboratory results, because cells in vitro do not mimic
correctly the in vivo environment, and can only pro-
vide partial explanations of PRP biology. In fact, the
in vivo conditions involve the impact of PRP on sever-
al cell types present in the host tissues; also relevant
is the dynamic influence of PRP in the innate immune
response, and in precursor cell migration. These are
few among the simultaneously occurring events that
cannot be mimicked in cell culture models. But de-
spite important limitations of in vitro studies, we still
can learn some lessons. Any formulation of PRP
stimulates MSC activation, but currently there is no
link with a single molecule and proliferation or migra-
tion or differentiation. The molecular pool released
from PRPs is very complex, and experimental design
for in vitro experiments to achieve meaningful results
is challenging. Many gaps of knowledge need to be
addressed in vitro in order to achieve enough infor-
mation useful for translational purposes.
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